---
layout: default
title: Anamirta Cocculus Whole Ascorbic Acid Chamaelirium
parent: 僅模型預測 (L5)
nav_order: 312
evidence_level: L5
indication_count: 0
---

# Anamirta Cocculus Whole Ascorbic Acid Chamaelirium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Herbal-Nutritional Complex: Evaluation Could Not Be Completed

## One-Sentence Summary

This candidate is a complex multi-ingredient formulation composed of eight components including botanical extracts (Anamirta cocculus, Chamaelirium luteum, Citrus limon, Rosa canina, Strychnos ignatii), nutritional agents (Ascorbic acid, Zinc), and Phosphoric acid.
The TxGNN pipeline returned **no predicted indications** for this entry, and the drug holds **no market authorization** in Taiwan nor any associated approvals on record.
As a result, a full repurposing evaluation cannot be completed at this stage; this report documents the data gaps and recommended remediation steps.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no model output, no studies |
| Market Status | Not Marketed (未上市) |
| Number of Approvals | 0 |
| Recommended Decision | **Hold** |

---

## Why Evaluation Cannot Proceed

This candidate presents three compounding obstacles that prevent a standard repurposing assessment:

**1. Unresolvable identity at the compound level.** The submission contains eight distinct ingredients listed as a single drug entry. TxGNN operates on single-molecule DrugBank nodes; a multi-ingredient string of this form cannot be mapped to the knowledge graph. No DrugBank ID was retrieved, which means neither the KG-based nor the DL-based prediction pathway could execute.

**2. No regulatory anchor.** The absence of any approved indication — in Taiwan or elsewhere — means there is no pharmacological baseline from which to reason about mechanism-to-new-indication transfer. Strychnos ignatii (Ignatius bean), for example, contains strychnine and brucine and has a documented toxicity profile, but without a formalized approval or dosage form on record, the safety boundary cannot be established.

**3. Missing mechanism of action.** No MOA data was recovered from DrugBank. Without knowing the dominant pharmacological action of the combination (whether antioxidant, adaptogenic, alkaloid-mediated, or other), the TxGNN score cannot be interpreted even if one were generated in future runs.

---

## Safety Considerations

No safety data — warnings, contraindications, or drug-drug interactions — was available for this candidate. **Please refer to the individual component package inserts and pharmacopoeial monographs** (particularly for Strychnos ignatii and Anamirta cocculus, both of which contain potent alkaloids) before any further development work.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no prediction output for this entry because the multi-ingredient string could not be resolved to a single DrugBank node; without a prediction score, evidence level, or original indication, no repurposing hypothesis can be evaluated.

**To proceed, the following is needed:**

- **Decompose the combination.** Identify the therapeutically active lead compound(s) — most likely strychnine/brucine from *Strychnos ignatii* or the vitamin/mineral fraction — and resubmit each as a separate single-ingredient candidate.
- **Establish regulatory history.** Search TFDA, FDA, EMA, and homeopathic pharmacopoeia registers for any formal approval, OTC monograph, or dossier associated with this combination or its individual components.
- **Retrieve MOA via DrugBank API.** For each decomposed ingredient with a DrugBank ID, query `mechanism_of_action` and `pharmacodynamics` fields to establish a biological rationale.
- **Clarify formulation intent.** Determine whether this is a homeopathic product, a dietary supplement, or a traditional herbal medicine — the regulatory pathway and evidentiary standards differ substantially across these categories.
- **Safety pre-screen for alkaloid components.** *Strychnos ignatii* and *Anamirta cocculus* both carry narrow therapeutic indices; a toxicity pre-assessment should be completed before any clinical hypothesis is formed.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

